Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

JU INSIGHT: Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Phase II Clinical Trial Results

By: Michael T. Schweizer, MD; Lawrence True, MD; Roman Gulati, MS; Yibai Zhao, PhD; William Ellis, MD; George Schade, MD; Bruce Montgomery, MD; Sonia Goyal, MPH; Katie Nega, MPH, ARNP; Alexander K. Hakansson, BS; Yang Liu, PhD; Elai Davicioni, PhD; Kenneth Pienta, MD; Peter S. Nelson, MD; Daniel Lin, MD; Jonathan Wright, MD | Posted on: 16 Feb 2023

Schweizer MT, True L, Gulati R, et al. Pathological effects of apalutamide in lower-risk prostate cancer: results from a phase II clinical trial. J Urol. 2023;209(2):354-363.

Study Need and Importance

Active surveillance (AS) is a strategy aimed at mitigating the overtreatment of lower-risk prostate cancer. AS has been shown to be safe, and this approach allows many patients to avoid surgery or radiation therapy; however, conversion to local treatment still occurs in approximately 20%-50% of patients. As such, medical approaches to decrease attrition from AS are appealing. To that end, we conducted a clinical trial to assess the pathological effects of 3 months of apalutamide in men followed on AS.

Figure. Positive biopsy-free survival with 95% confidence limits (shaded gray areas).

What We Found

Twenty-three patients enrolled and 22 had repeat biopsy after 90 days of apalutamide. Overall, 59% of study subjects had no residual cancer on post-treatment biopsy, with a median time to first positive biopsy of 364 days (see Figure). The impact of apalutamide on quality of life was minimal and transient. Decipher, a genomic risk classifier, revealed that those with higher baseline genomic risk were more likely to have a negative biopsy post-treatment.

Limitations

This study was designed to evaluate for preliminary evidence that apalutamide was effective in men enrolled in AS. While we acknowledge that a negative biopsy is not a validated proxy for long-term outcomes, this was felt to be a reasonable endpoint given that the majority of AS programs only recommend local therapy following pathological reclassification. We also acknowledge that the small sample size of this study was a limitation.

Interpretation for Patient Care

Short course apalutamide was associated with a high negative biopsy rate in men enrolled in AS. Notably, the observed pathological effects were similar to those reported in a separate study testing long course (ie, 12 months) of enzalutamide in a similar patient population. Importantly, the impact on quality of life was minimal and transient. Based on these results, follow-up studies appear justified.

advertisement

advertisement